About Icagen
Icagen is a Healthcare company based in United States founded in 2003, and was acquired by Pfizer in July 2011. CRO for ion channel and transporter drug discovery and development. Icagen has raised $27.48 million across 19 funding rounds from investors including Pfizer, HHS and Taglich Brothers. Its focus areas include Biopharma Outsourcing, CRO and Drug Discovery. Its legal entity is ICAGEN, INC. Its competitors include Crown Bioscience, Alloy Therapeutics and NIH; 2 of its 3 listed competitors have raised funding.
Company details
Icagen partners with Biopharma companies to offer scientific expertise and access to technologies for ion channel and transporter drug discovery and development. Icagens growing tool box comprises a broad range of cell lines and technologies for ion channel and transporter research, capped by the label-free XRpro platform. XRpro technology, based on X-ray fluorescence, is a novel method that enables high throughput assessment of ion channels and transporters. The company was acquired by Pfizer in Oct 2011 and spun out again to XRPro in July 2015, which merged its own operations within the new company.
- Headquarters United States
- Stage Acquired
- SectorsHealthcare
- Website icagen.com
- Social LinkedIn X
- Acquired by Pfizer (Jul 2011)
- Legal Name Icagen, Inc.
Funding Insights of Icagen
Icagen has successfully raised a total of $27.48M across 19 strategic funding rounds. The most recent funding activity was a Series B round of $7.25 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $27.48M
- Total Rounds 19
- Last Round Series B — $7.25M
- First Round $358,611
(Sep 2007)
- Investors Count 2
Latest 10 of 19 funding rounds of Icagen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2018 | $7.25M | Series B | – | – | – |
| Sep 2018 | $15.25M | Debt – Conventional | – | – | – |
| Aug 2018 | $8M | Debt – Conventional | – | – | – |
| Aug 2018 | $500,000 | Series B | – | – | – |
| Apr 2018 | $2M | Series B | – | – | – |
| May 2017 | $2M | Series B | – | – | – |
| Apr 2017 | $1.5M | Series B | – | – | – |
| Jul 2016 | $1.15M | Series B | – | – | – |
| Jan 2015 | $8.86M | Series B | – | Taglich Brothers | – |
| May 2013 | $3.14M | Series A | – | – | – |
3 investors in total: 3 institutional.
Investors in Icagen
Icagen has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Pfizer, HHS and Taglich Brothers.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A brokerage firm focused on small cap market investments. | 1991 | taglichbrothers.com | Cold Spring Harbor, USA | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States |
Investor details for Icagen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Icagen
4 dated milestones of Icagen across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Icagen is founded.
- Funding First funding round of $359K.
- Exit Acquired by Pfizer.
- Funding Latest funding round, Series B, of $7.2M.
Competitors of Icagen
Icagen has 3 listed competitors in our database, 2 of them funded. They include Crown Bioscience, Alloy Therapeutics and NIH.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| crownbio.com | 2006 | Santa Clara, United States | $85.87M | 18 | Cancer and CVMD drugs are developed using PDX models. | |
| alloytx.com | 2017 | Lexington, United States | $157M | Drug discovery services are provided for therapeutic development. | ||
| nih.gov | 1887 | United States | Drug discovery services are provided to the biopharma sector. |
Detailed competitors of Icagen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Icagen
Websites that share an audience with Icagen (icagen.com).
Websites whose visitors overlap most with Icagen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| immunomedics.com | 100% | View details | |||
| chemocentryx.com | 100% | View details | |||
| lifetechnologies.com | 100% | View details | |||
| waters.com | 66% | 416.8K | #124,184 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Icagen (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Icagen
Complete news archive for Icagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Icagen
Icagen was founded in 2003 and raised its 1st funding round 4 years after it was founded.
Icagen is headquartered in United States.
Icagen is a funded company, having raised a total of $27.48M across 19 funding rounds to date. The company's 1st funding round was a Series A of $3.14M, raised on Sep 2007.
Annual revenue of Icagen is $13.58M as on Dec 31, 2018.
Icagen partners with Biopharma companies to offer scientific expertise and access to technologies for ion channel and transporter drug discovery and development. Icagens growing tool box comprises a broad range of cell lines and technologies for ion channel and transporter research, capped by the label-free XRpro platform. XRpro technology, based on X-ray fluorescence, is a novel method that enables high throughput assessment of ion channels and transporters. The company was acquired by Pfizer in Oct 2011 and spun out again to XRPro in July 2015, which merged its own operations within the new company.
Icagen's top competitors include Crown Bioscience, NIH and Alloy Therapeutics.
Icagen has 3 investors. Key investors include Pfizer, HHS, and Taglich Brothers.
Icagen operates through Icagen, Inc..
Yes. Icagen was acquired by Pfizer in July 2011.